Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)
Bristol Myers' Opdivo notches a double win against chemo in esophageal cancer, potentially setting up 1st-line nod
Bristol Myers Squibb is one of a group of drugmakers prepping for a tense FDA adcomm later this month to review a host of accelerated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
